Activating internal tandem duplication (ITD) insertions in the juxtamembrane domain of the FLT3 tyrosine kinase are found in about one fourth of patients with acute myeloid leukemia and have been shown to be an independent negative prognostic factor for survival. We show that sorafenib (BAY 43-9006, Nexavar) potently inhibits FLT3 enzymatic and signaling activities. In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation. In leukemia cell lines MV4-11 and EOL-1, sorafenib treatment resulted in decreased cell proliferation and inhibition of FLT3 signaling. The growth of the FLT3-independent RS4-11 cell line was only weakly inhibited by sorafenib. Cell cycle arrest and induction of apoptosis were observed upon treatment with sorafenib in MV4-11 and EOL-1 cells. The antitumor efficacy of sorafenib was evaluated against the MV4-11 leukemia grown subcutaneously in NCr nu/nu mice. Doses of 3 and 10 mg/kg administered orally for 14 days resulted in six and nine out of 10 animals with complete responses, respectively. The demonstration that sorafenib exhibits potent target inhibition and efficacy in FLT3-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.
Activating mutations in FLT3 are found in approximately 25% of acute myeloid leukemias (AML) and 5-10% of patients with myelodysplastic syndrome (MDS). 1, 2 These mutations are primarily internal tandem repeat domain (ITD) insertions within the juxtamembrane domain of the enzyme 3, 4 which lead to the constitutive activation of FLT3 and ligand-independent growth. 6, 7 Sorafenib (BAY 43-9006, Nexavar) is an oral multikinase inhibitor that targets tumor cell signaling and tumor angiogenesis. 5 Sorafenib was recently approved by the Food and Drug Administration for patients with advanced kidney cancer, and is continuing to be evaluated in other tumor types. In the present study, we report that sorafenib potently inhibited FLT3 enzymatic and cellular activities and induced significant tumor growth inhibition and regressions of subcutaneously implanted FLT3-ITD containing tumors in athymic mice. These results furnish evidence that sorafenib may provide therapeutic benefit to patients with FLT-3-driven malignancies.
Materials and methods

Cell lines
RS4;11, MV4-11 and EOL-1 cells were obtained from the DSMZ (Braunschweig, Germany). Cells were grown in Rosewell Park Memorial Institute 1640 (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) (Fisher Scientific, Pittsburgh, PA, USA). MV4-11 cells were supplemented with 5 ng/ml of GM-CSF (BioSource, Cambridge, MA, USA).
Cloning and expression of FLT3-WT and FLT3-ITD
Human full-length and cytoplasmic (571-993) FLT3 cDNAs were isolated from a human fetal brain cDNA library (Clontech, Mountain View, CA, USA) by polymerase chain reaction (PCR). The FLT3-ITD mutation was introduced using the QuikChange site-directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol using primers 5 0 -GTT GATTTCAGAGAATATGAATATGATCTCAAATATGAATATGAT CTCAAATGGGAGTTTCCAAGA-3 0 and 5 0 -TCTTGGAAACTCC CATTTGAGATCATATTCATATTTGAGATCATATTCATATTCTC TGAAATCAAC-3 0 . To generate the D835Y mutant, oligonucleotide primers 5 0 -CTTTGGATTGGCTCGATATATCATGAGTGA TTCC-3 0 and 5 0 -GGAATCACTCATGATATATCGAGCCAATCCA AAG-3 0 were used. To generate the GST fusion proteins, FLT3-WT (571-993), FLT3-D835Y (571-993) and FLT3-ITD (571-993), cDNA fragments were ligated into the pFastBac1 vector (Invitrogen) together with a cDNA encoding GST. Recombinant baculoviruses expressing GST-FLT3-WT (571-993) and GST-FLT3-ITD (571-993) ITD were generated using the Bac-to-Bac Baculovirus Expression System (Invitrogen).
FLT3 Biochemical assay
The FLT3 biochemical FRET assay was performed in 96-well plates and measured the ability of the enzyme to phosphorylate biotinylated poly-Glu-Tyr. The reactions were carried out in a 100 ml reaction with a final concentration of 5 mM ATP (Sigma, St Louis, MI, USA), 20 nM Poly-Glu-Tyr biotin (Cis Bio, Cedex, France), 1 nM Eu-PY20 antibody (Perkin-Elmer, Boston, MA), 12.5 nM streptavidin-APC (Perkin-Elmer, Boston, MA, USA), 50 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid, pH 7.5, 10 mM MgCl 2 , 0.1 mM ethylenediaminetetraacetic acid (EDTA), 0.1% bovine serum albumin (BSA), 0.1% b-mercaptoethanol, 0.5% dimethylsulfoxide (DMSO). Recombinant FLT3-WT 1 nM and FLT3-ITD were added to a final concentration of 1.25 and 1 nM, respectively. Incubations were performed at room temperature for up to 90 min and were stopped with the addition of EDTA to 10 mM. Plates were read on a Victor 3 instrument (Perkin-Elmer, Torrance, CA, USA) at 615 and 665 nm wavelength and the 665/615 nm ratio was calculated. IC 50 values were generated using Analyze5 (VisSim, Westford, MA, USA) software. Inhibition constants (K i ) were calculated using the Cheng-Pursoff equation (IC 50 ¼ K i *(S/K m þ 1)) in NLREG software.
Cell proliferation
Effects on cell proliferation were measured using Cell Titer Glo reagent (Promega, Madison, WI, USA) as described previously. 5 Cells were seeded at 3000 cells/well in a 96-well plate and grown at 371C in 5% CO 2 for 72 h.
Cell cycle analysis and apoptosis assays
For cell cycle analysis, MV4-11 cells were exposed to drug for 72 h and then trypsinized, fixed, treated with RNAse (Roche, Indianapolis, IN, USA) and stained with propidium iodide (PI) (Invitrogen) according to the manufacturer's protocol. Samples were analyzed by flow cytometry on a fluorescence-activated cell sorter (FACS) Calibur instrument (BD Biosciences, Franklin Lakes, NJ, USA). For apoptosis assays, MV4-11 cells were exposed to drug for 72 h and EOL-1 cells were exposed for 24 h. After compound treatment the cells were harvested and stained for apoptosis using the Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection Kit (BD Biosciences). Samples were analyzed by multicolor gating using a FACSCalibur Flow Cytometer (BD Biosciences).
Western blotting
Western blotting procedures and detection of phospho-FLT3 (Tyr591) were carried out as described previously. 5 For Stat5, phospho-STAT5 (Tyr694) (Cell Signaling, Beverly, MA, USA) and total Stat5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies were used at a 1:1000 dilution. For detection of both phospho-extracellular signal-regulated kinase (ERK) and total ERK1/2, antibodies (Cell Signaling) were used at a 1:1000 dilution. For PDGFR, phospho-PDGFR (Tyr857) and total PDGFR (Santa Cruz) were used.
FLT3 receptor autophosphorylation ELISA
Enzyme-linked immunosorbent assay (ELISA) assay procedures and reagents were used as described previously. 5 The 96-well plates were prepared by adding 100 ml/well of FLT-3 antibody (R&D Systems Inc., Minneapolis, MN, USA) diluted in phosphate-buffered saline (PBS) to a final concentration of 3 mg/ml. The detection antibody used was the anti-phosphotyrosine antibody 4G10, horseradish peroxidase (HRP)-conjugated (Upstate, Waltham, MA, USA) at 20 ng/well diluted in PBS containing 3% BSA. Chromogenic revelation was done using tetramethylbenzidine (TMB) substrate (Sigma) and the plates were read on a Victor3 instrument at 450 nm. Data analysis was performed using Analyze5.
Tumor xenograft experiments
The procedures for establishing tumor xenografts and the dosing of sorafenib were carried out as described previously 5 in accordance with Bayer IACUC, State and Federal guidelines. Female NCr nu/nu mice were implanted subcutaneously in the right flank with 5 Â 10 6 MV4-11 cells. For the in vivo studies, the tosylate salt of sorafenib was administered p.o. on a q.d. Â 9 schedule at dose levels of 0.3, 1, 3 and 10 mg/kg. There were 10 mice per control or treatment group. Treatment was initiated when mice had established tumors ranging in size from 75 to 126 mg.
Tumor mode of action studies MV4-11 tumors (n ¼ 3 per group) were implanted as described earlier and once the tumors reached 150-200 mm 2 in size, animals were treated with sorafenib (administered orally at 3 or 10 mg/kg) or vehicle. Two treatments were administered 24 h apart and tumors were collected 3 h after that second treatment. The tumors were cut in half and one half was homogenized for immunoprecipitation/Western blot analysis and the other half was fixed and processed for immunohistochemistry as detailed previously. 5 For STAT5 immunoprecipitation, 500 mg of proteins were incubated with STAT5 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 41C and with protein A/ G-agarose for 2 h at 41C. STAT5 phosphorylation was measured by probing with an anti-pSTAT5 (Tyr694) antibody from Upstate Biotechnology. For the immunohistochemical staining of phosphorylated Histone H3, a rabbit polyclonal phosphoHistone H3 (Ser10) (Cell Signaling) was used at a dilution of 1:50 with Dako Antibody Diluent (DakoCytomation, Carpinteria, CA, USA). Staining was performed using the Envision Plus HRP DAB System (DakoCytomation). The staining procedure was carried out according to the manufacturer's protocol. The slides were counterstained with Mayer's hematoxylin.
Results
Sorafenib is a potent inhibitor of FLT3 WT and ITD enzymatic and functional activities
As shown in Table 1 Cell viability assays were performed in media containing 10% FBS. Cell Titer Glo (CTG, Promega) was used for quantification.
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Treatment of MV 4-11 cells (FLT3-ITD) 7 with sorafenib potently inhibited cell proliferation in a dose-dependent manner with an IC 50 of 0.88 nM (Table 1) . Potent antiproliferative effects of sorafenib were also observed with EOL-1 cells which overexpress FLT3 wild-type receptor and also possess an FLT3 ligand (FL) autocrine loop. 8 In contrast, FLT-3-independent RS4;11 cells containing low levels of wild-type FLT3 9 were weakly inhibited by sorafenib, with an IC 50 value of 12 mM ( Table 1) . The difference in sensitivity of the MV4-11 and EOL-1 cells as compared to the RS4;11 cells suggests that a specific proliferative signaling pathway was being inhibited in FLT3-dependent cells by sorafenib.
Sorafenib induces cell cycle arrest and apoptosis in FLT3-ITD leukemic cells
Induction of apoptosis following treatment of FLT3-ITD leukemic MV4-11 and EOL-1 cells was assayed by flow cytometry. In MV4-11 cells, a concentration of 100 nM sorafenib induced 43.675.2% of the cells to undergo apoptosis whereas in EOL-1 cells a concentration as low as 10 nM of sorafenib induced 89.2971.8% of the cells to become apoptotic (Figure 1a) . EOL-1 cells have been recently reported to also contain a FIP1L1-platelet-derived growth factor receptor (PDGFR) alpha translocation, which results in a constitutive activation of PDGFRalpha. 10 We have reported previously that sorafenib potently inhibits PDGFR. 5 Inhibition of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant by sorafenib has also been recently reported by Lierman et al.
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Dual inhibition of PDGFRalpha and FLT3 in EOL-1 by sorafenib may account for the extreme sensitivity of these cells to the drug. Cell cycle analysis of sorafenib-treated MV4-11 cells afterPI staining confirmed the induction of apoptosis with 20.370.5% of the cells in the sub-G 0 compartment at 100 nM sorafenib and 61.770.8% of the cells in the sub-G 0 compartment at 10 mM (Figure 1b) . Treatment with sorafenib also induced a dosedependent cell cycle arrest with an increase in the percentage of cells in G 0 /G 1 from 52.770.9% (DMSO control) to 66.871.5% (100 nM inhibitor). A parallel reduction of the percentage of cells in S phase and G 2 /M phase was also seen (Figure 1b) . Taken together, these data indicate that sorafenib inhibits the proliferation of FLT3-driven leukemic cells by inducing cell cycle arrest and apoptosis.
Sorafenib inhibits FLT3-WT and -ITD-dependent signaling
The effect of sorafenib on FLT3-dependent downstream signaling pathways was investigated in FLT3-WT and FLT3-ITD stably transfected HEK293 cells. Tyrosine autophosphorylation in FLT3-WT containing cells was dependent on the addition of FL, whereas in FLT3-ITD containing cells FLT3 was constitutively phosphorylated (Figure 2a ). Both FL-induced and constitutive autophosphorylated FLT3 receptor was inhibited by low (Figure 2a) . The effects of sorafenib on FLT3 autophosphorylation was also investigated using an ELISA assay. Sorafenib inhibited FLT3-ITD receptor tyrosine phosphorylation in a dose-dependent manner following a 2-h treatment with drug. In three separate experiments, IC 50 values ranged from 4 to 8.3 nM, with a mean of 5.5 nM ( Table 1) .
The effect of constitutive and FL-induced phosphorylation of FLT3-ITD and FLT3-WT respectively on downstream signaling cascades was also investigated. Whole-cell lysates were immunoblotted with phosphospecific and total Stat5 and ERK1/2 antibodies. Both ligand-induced (FLT3-WT) and constitutive (FLT3-ITD) activation of FLT3 led to the phosphorylation of Stat5 and ERK1/2 (Figure 2a ). Both downstream phosphorylation events were inhibited by low nanomolar concentrations of sorafenib.
To further characterize the effects of sorafenib on endogenous FLT3-mediated signaling in leukemic cells, MV4-11 and EOL-1 cells were treated with increasing concentrations of sorafenib for 2 h, after which time the cells were lysed and the levels of FLT3 and Stat5 phosphorylation were monitored by Western blot analysis. As observed earlier in 293/FLT3-ITD cells, sorafenib, at low nanomolar concentrations, inhibited FLT3-driven ERK1/2 and Stat5 phosphorylation in both MV4-11 and EOL-1 cells (Figure 2b ). In EOL-1 cells, PDGFRalpha autophosphorylation was also potently inhibited by sorafenib (Figure 2c ), confirming that dual inhibition of FLT3 and PDGFRalpha signaling was blocked by the drug in this cell line.
Sorafenib induces regression of subcutaneous FLT3-ITD tumors in athymic mice
The antitumor activity of sorafenib was evaluated using an FLT3-ITD subcutaneous tumor xenograft model in athymic mice. Groups of 10 tumor-bearing mice were either left untreated or treated with vehicle alone or with sorafenib administered orally at 0.3, 1.0, 3 or 10 mg/kg. The compound was well tolerated and no significant body weight loss or lethality was observed. The antitumor activity of sorafenib was dose dependent. The 0.3 mg/kg sorafenib did not produce a significant tumor growth delay or tumor regressions (Figure 3a) , whereas at the 1 mg/kg dose level one out of 10 animals had a complete regression (CR) and the overall tumor growth delay was approximately equivalent to the duration of treatment. Treatment with 3 or 10 mg/kg resulted in six and nine out of 10 animals with complete responses, respectively (Figure 3a) . These results were confirmed in a second independent experiment (data not shown).
To further characterize the in vivo biological activity of sorafenib, MV4-11 tumors were harvested, homogenized and analyzed by immunoprecipitation/Western blot analysis for phospho-Stat5. Phosphorylation of STAT5 was completely abolished in MV4;11 tumors 3 h after the second administration of sorafenib (Figure 3b ). The inhibition of Stat5 phosphorylation in MV4;11 tumors by sorafenib is consistent with the inactivation of FLT3 signaling by the drug as Stat5 has been reported to be the main downstream effector of FLT3-ITD in vivo.
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Figure 2 Sorafenib inhibits FLT3-dependent signaling. (a) HEK293 cells that were stably transfected with either wild-type FLT3 (FLT3-WT) or FLT3 with an internal tandem duplication (FLT3-ITD) were starved and then incubated with various concentrations of sorafenib or DMSO for 2 h, after which they received or did not receive FL.Cell lysates were subjected to Western blot analysis for phosphorylated (p) or total FLT3, ERK1/2 or Stat5. (b) Cell lysates were subjected to Western blot analysis for phosphorylated (p) or total FLT3, and Stat5. For phosho-FLT3 and phospho-Stat5 detection in MV4-11, polyclonal primary antibodies, a secondary biotinylated anti-rabbit immunoglobulin G (IgG) and avidin HRP were used for detection. (c) For EOL-1 cells, the same primary phospho-FLT3 and phospho-Stat5 primary antibodies and secondary HRP-conjugated anti-rabbit IgG antibodies were used.
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Tumors were also analyzed by anti-phospho-histone H3 immunohistochemistry to determine the effects on cell cycle progression. MV4-11 tumor cells from the untreated or vehicletreated groups stained strongly with phospho-histone H3, indicating a tumor with a high proliferation index (Figure 3c ). Tumors from animals treated with sorafenib showed a marked reduction in phospho-histone H3 staining (Figure 3c ). These data are consistent with a potent inhibition of MV4-11 tumor cell proliferation induced by sorafenib.
Discussion
The prognostic significance of FLT3-ITD mutations in clinical studies suggests that it plays a important role in AML. 14 Consistent with a previous report describing high-affinity binding of sorafenib to FLT3-WT, 6 we report that sorafenib can inhibit FLT3-ITD kinase activity and cell signaling and demonstrates potent antitumor efficacy in the MV4-11 tumor xenograft model. Sorafenib is among the most potent inhibitors of FLT3-ITD kinase described to date. Interestingly, sorafenib was nearly 10 times more potent at inhibiting phosphorylation of FLT3, Stat5 and ERK1/2 in FLT3-ITD 293 cells than in FLT3-WT 293 cells. Sorafenib also potently inhibits the enzymatic activity of FLT3 activation loop mutant D835Y, suggesting that this compound may have activity against multiple mutant forms of FLT3, something also supported by our modeling of sorafenib against FLT3 (Auclair et al., Proc Am Assoc Cancer Res, 2005; 46: 1409; 5991). Differential sensitivity of wild-type and mutant forms of FLT3 to inhibitors has been reported previously. 15 The selectivity of sorafenib for FLT3-ITD versus FLT3-WT may have significant implications for therapy given the association of Antitumor activity of sorafenib D Auclair et al FLT3-ITD with disease progression or relapse of AML. 14, 16 In a randomized phase I trial of sorafenib in patients with MDS or AML, clinical effects (reduction in peripheral blood and bone marrow blasts) were seen in 4/27 evaluable patients with one confirmed complete response lasting three cycles (Crump et al. J Clin Oncol., 2004; 22: 6611). In that study, biological activity was assessed in blasts from 14 patients and pathway inhibition was observed in 5/14 patients. The potential therapeutic role of sorafenib in AML patient with an FLT3-ITD mutation is being addressed in a phase II follow-up trial.
Several small-molecule inhibitors with activity against FLT3 have been recently described (see Levis and Small 17 for a recent review). Each inhibitor has its own spectrum of activity for other kinases including VEGFR2, PDGFR, KIT and protein kinase C (PKC). One unique feature of sorafenib compared to other inhibitors of FLT3 is its activity against Raf kinase. The Raf/Mek/ ERK pathway has been shown to be potentially involved in AML physiopathology. 18, 19 In a recent study looking at AML samples from 42 patients, markedly elevated phospho-ERK levels were found in 83.3% of the AML samples and treatment with a MEK inhibitor resulted in significantly decreased phospho-ERK levels, which was associated with growth arrest but not apoptosis induction. 20 On that last point, other studies on pharmacological inhibition of the Ras/Raf/Mek pathway in AML cells in vitro have reported conflicting data, with some studies showing mostly cell cycle arrest without immediate significant induction of apoptosis in treated cells 21, 22 whereas other studies have demonstrated induction of apoptosis. 23, 24 Sorafenib also has potent activity against kinases reported to potentially be contributing to AML physiopathology such as PDGFR, KIT and VEGFR. [25] [26] [27] Although the selective antiproliferative and proapoptotic effects of sorafenib in FLT3-dependent cells versus FLT3-independent cells as well as the potent inhibition of Stat5 phosphorylation, a major downstream target of FLT3-ITD, 28 argue for FLT3 as an important driver of the activities reported, it is likely that the inhibition of other kinases by sorafenib may also contribute to the observed antiproliferative effects. It is noteworthy that MV4-11 cell proliferation was inhibited with an IC 50 of 0.88 nM, 3-5-fold less than the IC 50 for inhibition of FLT3. Also, the benefits of a multi-kinases inhibitor like sorafenib are perhaps best illustrated by the activity of sorafenib in EOL-1 cells where inhibition of proliferation and induction of apoptosis are observed at subnanomolar concentrations of the drug. It has been reported in a recent study that in primary blasts (irrespective of their FLT3 status) treated with FLT3 inhibitors, induction of cytotoxicity correlated closely with deactivation of Stat5 and ERK and cases were observed where minimal cytotoxic responses were seen when Stat5 and/or ERK activation persisted despite complete inhibition of FLT3. 29 Given the multifactorial pathogenesis of AML and these emerging data suggesting that targeted inhibition of FLT3 may not, in some cases, be sufficient in itself to induce cytotoxicity, multi-kinases inhibitors like sorafenib are therefore attractive agents.
In summary, the demonstration that sorafenib exhibits potent target inhibition and efficacy in FLT3-driven tumors suggests that this compound may have therapeutic benefit for patients with FLT3-driven leukemias.
